Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2021-10-25 00:00:00 ET · period of report 2021-10-21 · accession 0001209191-21-061485 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-10-25 | 2021-10-21+ | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale+OE | $59.55 | -60.0K | 393.8K | -13% | -$3.57M |
| DM | 2021-10-25 | 2021-10-21+ | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $2.89 | +60.0K | 423.8K | +16% | +$173.6K |
| DM | 2021-10-25 | 2021-10-21+ | FATE | Wolchko J Scott | Pres, CEO, Dir | M - OptEx | $0.00 | -60.0K | 50.0K | -55% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-21 | S | D | 14,765 | $60.63 | 393,793 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.31 to $61.26 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2021-10-21 | M | A | 30,000 | $2.73 | 423,793 | D | — | — | |
| 3 | Common | Common Stock | 2021-10-21 | S | D | 15,235 | $59.82 | 408,558 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.31 to $60.30 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2021-10-22 | S | D | 30,000 | $58.88 | 393,793 | D | — | — | |
| 5 | Common | Common Stock | 2021-10-22 | M | A | 10,000 | $2.73 | 403,793 | D | — | — | |
| 6 | Common | Common Stock | 2021-10-22 | M | A | 4,846 | $4.84 | 408,639 | D | — | — | |
| 7 | Common | Common Stock | 2021-10-22 | M | A | 15,154 | $2.70 | 423,793 | D | — | — | |
| 8 | Derivative | Stock Option (Right to Buy) | 2021-10-22 | M | D | 15,154 | $0.00 | 99,446 | D | $2.70 · — to 2026-01-11 | 15,154 Common Stock | (F4) This option is fully vested. |
| 9 | Derivative | Stock Option (Right to Buy) | 2021-10-22 | M | D | 4,846 | $0.00 | 0 | D | $4.84 · — to 2025-01-04 | 4,846 Common Stock | (F4) This option is fully vested. |
| 10 | Derivative | Stock Option (Right to Buy) | 2021-10-21 | M | D | 30,000 | $0.00 | 60,000 | D | $2.73 · — to 2027-01-03 | 30,000 Common Stock | (F4) This option is fully vested. |
| 11 | Derivative | Stock Option (Right to Buy) | 2021-10-22 | M | D | 10,000 | $0.00 | 50,000 | D | $2.73 · — to 2027-01-03 | 10,000 Common Stock | (F4) This option is fully vested. |